Dazodalibep is under clinical development by Horizon Therapeutics and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dazodalibep’s likelihood of approval (LoA) and phase transition for Sicca Syndrome (Sjogren) took place on 20 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dazodalibep Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dazodalibep overview

Dazodalibep (VIB-4920, MEDI-4920) is under development for the treatment of focal segmental glomerulosclerosis, kidney transplant rejection, rheumatoid arthritis and Sjogren's syndrome. It is administered by intravenous route. The drug candidate is a biological agent derived from third fibronectin type III domain of human tenascin C antagonizing the CD40 ligand. It is an anti-CD40L-Tn3 fusion protein.

Horizon Therapeutics overview

Horizon Therapeutics formerly Horizon Pharma, is a pharmaceutical company, which develops and commercializes medical products for the treatment of rare, autoimmune, arthritis and severe inflammatory diseases. It markets medicines through its orphan, primary care and rheumatology business units. A few of the company’s marketed products include Actimmune, Buphenyl, Duexis, Krystexxa, Pennsaid, Procysbi, Quinsair, Ravicti, Rayos, Tepezza, Uplinza, and Vimovo. Horizon Therapeutics provides products and services to patients and healthcare professionals in the US. The company operates through offices in the US, Switzerland, Luxembourg, Bermuda, Germany, Canada, and Israel. Horizon Therapeutics is headquartered in Dublin, Ireland.

Quick View Dazodalibep LOA Data

Report Segments
  • Innovator
Drug Name
  • Dazodalibep
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genito Urinary System And Sex Hormones
  • Immunology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.